In this study, we used ever tranciptase-polymerase chain reaction (RT-PCR) to compare the expression of mRNAs enoding endotlhn-I (ET-i), endothelin reptors type A (ETA-R) and type B (ETR-R) and ET-l1degrading enzyme neutral endopptidase 24.11 (NEP) al., 1989). Although ET-1 was originally isolated from cultured endothelial cells, it has become evident that the ETs are widely distributed in different tissues and organs (Nunez et al., 1990) . The different potencies of the three isoforms of the ET family opened up the possibility of the existence of multiple ET receptor (ET-R) subtypes as well. Two distinct ET receptors with different specificities have been cloned (Arai et al., 1990; Sakurai et al., 1990). The type A endothelin receptor (ETA-R) has high affinity for ET-1 and ET-2 but little cross-reactivity with ET-3 and sarafotoxin S6c, whereas type B receptor (ETB-R) is non-selective with similar affinities for the different ETs and sarafotoxin S6c (Sakurai et al., 1992) . A third ET-R subtype with superhigh affinity has been described but not yet cloned (Sokolovsky et al., 1992) . The ET-Rs are widely distributed in cell lines and organs, but their relative abundance in different tisues varies. ETB-R dominates in hippocampus, whereas ETA-R dominates in the uterus (Williams et al., 1991). Neutral endopeptidase 24.11 (NEP), also calW enkephalinase, is a zinc-containing plasma membrane enzyme that efficiently degrades a number of smal bioactive peptides, including the ETs (Sokolovskly et al., 1990; Vijayaraghavan et al., 1990) .
Endothelin (ET) is a 21 amino acid peptide which was first described in 1988 as a potent vasoconstrictor localised in vascular endothelium . Subsequently, three ET isopepiades, called ET-1, ET-2 and ET-3, with different biological activities, have been identified by screening the huiman genomic DNA library (Inoue et al., 1989) . Although ET-1 was originally isolated from cultured endothelial cells, it has become evident that the ETs are widely distributed in different tissues and organs (Nunez et al., 1990) . The different potencies of the three isoforms of the ET family opened up the possibility of the existence of multiple ET receptor (ET-R) subtypes as well. Two distinct ET receptors with different specificities have been cloned (Arai et al., 1990; Sakurai et al., 1990) . The type A endothelin receptor (ETA-R) has high affinity for ET-1 and ET-2 but little cross-reactivity with ET-3 and sarafotoxin S6c, whereas type B receptor (ETB-R) is non-selective with similar affinities for the different ETs and sarafotoxin S6c (Sakurai et al., 1992) . A third ET-R subtype with superhigh affinity has been described but not yet cloned (Sokolovsky et al., 1992) . The ET-Rs are widely distributed in cell lines and organs, but their relative abundance in different tisues varies. ETB-R dominates in hippocampus, whereas ETA-R dominates in the uterus (Williams et al., 1991) . Neutral endopeptidase 24.11 (NEP) , also calW enkephalinase, is a zinc-containing plasma membrane enzyme that efficiently degrades a number of smal bioactive peptides, including the ETs (Sokolovskly et al., 1990; Vijayaraghavan et al., 1990) .
In the human endometrium, ET-I has been shown to be produced by both stromal and epithelial cells, with icreased concentrations observed before and during menstruation (Economos et al., 1992) . The mRNAs for ET-1, ET-2 and ET-3 have been detected in hunman endometrium throughout the menstual cycle (O'Reilly et al., 1992) . Also, pregnancy endometrium (decidua) synthesises EU-i (Kubota et al., 1992) . The expression of ETA-R and ET,,rR mRNA in the endometrium varies with the phase of the menstrual cycle, the ratio of ETA-R to ETB-R being lowest in late secretory phase (O'Reilly et al., 1992) . NEP is present in the human endometrium throughout the m strual cycle (Head et al., 1993) . The specific activity of the enzyme is correlated with the plasma levels of progesterone and is highest in early and mid-secretory phase (Casey et al., 1991 (Kusuhara et al., 1990; Pekonen et al., 1992) , but information on ET-R mRNA expression in cancer tissue is scarce. In colon cancer, decreased ET receptor activity has been reported (Inagaki et al., 1992) . Expression of NEP mRNA is typical for leukaemias, but has also been demonstrated in other malignancies such as melanomas, gliomas and mesenchymal tumours (Carrel et al., 1983; Mechtersheimer and M61ler, 1989; Monod et al., 1992 (Table I) .
Statistics
Student's t-test for non-paired samples was used when mRNA expression in cancer tissues and normal tissues was compared.
Results
The 30 cycle PCR products were within the linear logarithmic phase of the amplification curve for ET-l, NEP. ETA-R and ETB-R (Figure 1 ). The sizes of the RT-PCR products were as predicted from the genomic maps (Table I and Figure 2 ). By Southern hybridisation single bands corresponding to the RT-PCR bands in agarose gels were seen in each case (results not shown). The ET-1 mRNA levels in human endometrial cancer tissues and samples of normal endometrium did not differ (P = 0.959) (Figure 3 ). In contrast, both ETA-R and ETB-R mRNA levels were significantly lower (P<0.001) in endometrial cancer tissues than in normal endometrial tissues (Figure 4) , and NEP mRNA could not be detected in any of endometrial cancer tissues ( Figure  3 ). This was in striking contrast to the results from normal endometrial tissues, in which NEP mRNA was detectable in each tissue studied (Figure 3 , P<0.001). Figure 3 . The samples are the same as in Figure 3 .
has been shown that some pulmonary tumours express ET-1 mRNA (Giaid et al.. 1990) (Baley et al., 1990 (Schiff et al., 1993) .
The relative levels of ET-1 mRNA in different endometrial cancer cell lines are reflected in their ET-1 secretion, as shown previously (Pekonen et al., 1992 In this study, they were all post-menopausal. It is obvious that post-menopausal endometrium differs from premenopausal endometrium regarding autocrine and paracrine factors regulated by ovarian steroid hormones. It appears that the NEP mRNA expression in the endometrium is not regulated by oestrogens, since NEP mRNA levels in post-menopausal endometrium have been reported to be similar to those in proliferative phase endometrium (Head et al., 1993) .
Even progesterone's role in the regulation of NEP remains unclear. Immunoreactive NEP was weak in proliferative endometrium, strong in mid-secretory endometrium and almost non-existent in predecidualised/decidualised endometrium in spite of high serum progesterone levels (Head et al., 1993) . Thus, NEP expression in the endometrium appears to be more differentiation than hormone dependent. The low expression of ET-R in endometrial cancer implies decreased ET action and, consequently, decreased vasoconstriction in cancer tissue compared with normal endometrium. Whether or not the lack of NEP has a role in endometrial carcinoma is more difficult to speculate, since NEP hydrolyses ET-1 as well as a number of other bioactive peptides, which may have effects on tumour growth.
